DoD Awards $10+ Mil Grant to V. Craig Jordan for Research on New Breast Ca Treatment

Publication
Article
OncologyONCOLOGY Vol 20 No 11
Volume 20
Issue 11

Fox Chase Cancer Center's V. Craig Jordan, OBE, PHD, DSC, has received a $10.7 million grant from the Department of Defense (DoD) Breast Cancer Research Program for a Breast Cancer Center of Excellence focused on developing a new treatment model for breast cancer to reverse the eventual development of resistance to antiestrogen therapy.

Fox Chase Cancer Center's V. Craig Jordan, OBE, PHD, DSC, has received a $10.7 million grant from the Department of Defense (DoD) Breast Cancer Research Program for a Breast Cancer Center of Excellence focused on developing a new treatment model for breast cancer to reverse the eventual development of resistance to antiestrogen therapy. The 5-year multidisciplinary project, intended to encompass both laboratory research and clinical trials, involves scientists and physicians at Fox Chase and three other institutions, representing four task teams.

Project Goals

"The DoD Breast Cancer Research Program is pleased to support this innovative project by Dr. Jordan, his collaborators and Fox Chase Cancer Center to address a critical issue in breast cancer—the identification of new therapeutic drugs to treat women with breast cancer," said Col. Janet R. Harris, MDN, PHD, director of the Congressionally Directed Medical Research Programs administering the DoD Breast Cancer Research Program. "Through this project, new treatments will be brought from the laboratory to stage I and II clinical trials, facilitating the process for making new breast cancer therapeutic drugs available sooner."

This is Fox Chase's second Center of Excellence grant received in 5 years. In 2001, the Department of Defense awarded a $6 million dollar grant for the development of the nation's first Behavioral Center of Excellence for Breast Cancer Research.

"In the past 25 years, the estrogen receptor has proven to be an important target for the treatment of breast cancer," Jordan explained. "However, there is a need for a new strategy to reverse the eventual development of antihormonal drug resistance, to ensure that effective agents can ultimately be used indefinitely."

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.